Who is sponsoring NCT02693626?

NCT02693626 is sponsored by Central South University.

What drugs are being tested in NCT02693626?

Interventions in NCT02693626: intensive cessation message, Not intensive cessation message.

What condition does NCT02693626 study?

NCT02693626 studies Smoking Cessation.

Is NCT02693626 still recruiting?

NCT02693626 is currently completed. Last updated 6 February 2019.

Last reviewed 2019-02-06 · How we verify

NCT02693626: HQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Happy Quit for Smoking Cessation in China

Completed NA Last updated 6 February 2019

What this trial tests

NA trial testing intensive cessation message in Smoking Cessation in 1,369 participants. Completed in 27 November 2017.

Timeline

17 August 2016

Primary endpoint
27 November 2017

27 November 2017

Quick facts

Lead sponsor	Central South University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	1,369
Start date	17 August 2016
Primary completion	27 November 2017
Estimated completion	27 November 2017

Drugs / interventions tested

intensive cessation message
Not intensive cessation message

Conditions studied

Smoking Cessation — all drugs for Smoking Cessation →

Sponsor

Central South University

Who can join

18 and older, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this proposed three-year (January 01, 2016 to December 31, 2018) project is to assess whether a program of widely accessed mobile phone-based text message interventions ('Happy Quit') will be effective at helping people in China who smoke, to quit. Based on the efficacy of previous studies in smoking cessation, it is hypothesized that 'Happy Quit' will be an effective, feasible and affordable smoking cessation program in China.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of a text-messaging-based smoking cessation intervention ("Happy Quit") for smoking cessation in China: A randomized controlled trial.
Liao Y, Wu Q, Kelly BC, Zhang F, et al · · 2018 · cited 67× · PMID 30562352 · DOI 10.1371/journal.pmed.1002713
The efficacy of mobile phone-based text message interventions ('Happy Quit') for smoking cessation in China.
Liao Y, Wu Q, Tang J, Zhang F, et al · · 2016 · cited 25× · PMID 27543164 · DOI 10.1186/s12889-016-3528-5
Predictors of long-term abstinence in a randomized controlled trial of smoking cessation by mobile phone text messaging ('Happy Quit') in China.
Liao Y, Wang Y, Tang J, Wu Q, et al · · 2022 · cited 4× · PMID 35991840 · DOI 10.18332/tpc/152255

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting

Other Central South University trials

Trials by the same sponsor.

NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02693626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central South University
Last refreshed: 6 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02693626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing